S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

Insmed Stock Forecast, Price & News

+0.84 (+2.25 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $38.13
50-Day Range
MA: $39.90
52-Week Range
Now: $38.13
Volume1.45 million shs
Average Volume871,405 shs
Market Capitalization$3.93 billion
P/E RatioN/A
Dividend YieldN/A
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
Insmed logo


Insmed (INSM) Misses Q4 EPS by 30c - StreetInsider.com
February 25, 2021 |  streetinsider.com
Form 424B5 INSMED Inc - StreetInsider.com
February 25, 2021 |  streetinsider.com
Insmed to Present at Two March Conferences - Yahoo Finance
February 24, 2021 |  finance.yahoo.com
Insmed to Present at Two March Conferences
February 24, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:INSM
Year FoundedN/A



Sales & Book Value

Annual Sales$136.47 million
Book Value$2.93 per share


Net Income$-254,340,000.00
Net Margins-145.14%


Market Cap$3.93 billion
Next Earnings Date4/29/2021 (Estimated)


Overall MarketRank

1.20 out of 5 stars

Medical Sector

872nd out of 1,968 stocks

Pharmaceutical Preparations Industry

413th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
+0.84 (+2.25 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INSM News and Ratings via Email

Sign-up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Insmed (NASDAQ:INSM) Frequently Asked Questions

Is Insmed a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Insmed stock.
View analyst ratings for Insmed
or view top-rated stocks.

What stocks does MarketBeat like better than Insmed?

Wall Street analysts have given Insmed a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Insmed wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Insmed's next earnings date?

Insmed is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for Insmed

How were Insmed's earnings last quarter?

Insmed Incorporated (NASDAQ:INSM) announced its earnings results on Thursday, February, 25th. The biopharmaceutical company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by $0.33. The biopharmaceutical company had revenue of $41.42 million for the quarter, compared to the consensus estimate of $41.44 million. Insmed had a negative trailing twelve-month return on equity of 79.58% and a negative net margin of 145.14%. The business's revenue was down 9.4% compared to the same quarter last year. During the same period last year, the business posted ($0.59) EPS.
View Insmed's earnings history

How has Insmed's stock price been impacted by COVID-19 (Coronavirus)?

Insmed's stock was trading at $21.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, INSM stock has increased by 79.4% and is now trading at $38.13.
View which stocks have been most impacted by COVID-19

What price target have analysts set for INSM?

7 Wall Street analysts have issued 1-year price targets for Insmed's shares. Their forecasts range from $44.00 to $60.00. On average, they expect Insmed's share price to reach $53.86 in the next year. This suggests a possible upside of 41.2% from the stock's current price.
View analysts' price targets for Insmed
or view top-rated stocks among Wall Street analysts.

Who are Insmed's key executives?

Insmed's management team includes the following people:
  • Mr. William H. Lewis J.D., Pres, CEO & Chairman (Age 50)
  • Mr. Paolo Tombesi, Chief Financial Officer (Age 55)
  • Ms. Christine A. Pellizzari J.D., Chief Legal Officer & Corp. Sec. (Age 51)
  • Mr. Roger Adsett, Chief Commercial Officer (Age 50)
  • Dr. Paul D. Streck, Advisor (Age 55)

What is Will Lewis' approval rating as Insmed's CEO?

14 employees have rated Insmed CEO Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among Insmed's employees.

Who are some of Insmed's key competitors?

What other stocks do shareholders of Insmed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN).

What is Insmed's stock symbol?

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Who are Insmed's major shareholders?

Insmed's stock is owned by a number of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (9.48%), Janus Henderson Group PLC (5.72%), William Blair Investment Management LLC (3.64%), Baker BROS. Advisors LP (2.12%), Artisan Partners Limited Partnership (2.01%) and Lord Abbett & CO. LLC (1.97%). Company insiders that own Insmed stock include Alfred Altomari, Christine A Pellizzari, Donald J Hayden Jr, John Goll, John Soriano, Melvin Md Sharoky, Orlov S Nicole Schaeffer and William Lewis.
View institutional ownership trends for Insmed

Which major investors are selling Insmed stock?

INSM stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Janus Henderson Group PLC, Alliancebernstein L.P., Rice Hall James & Associates LLC, Baker BROS. Advisors LP, Hudson Bay Capital Management LP, GSA Capital Partners LLP, and C WorldWide Group Holding A S. Company insiders that have sold Insmed company stock in the last year include Alfred Altomari, Christine A Pellizzari, John Soriano, Melvin Md Sharoky, Orlov S Nicole Schaeffer, and William Lewis.
View insider buying and selling activity for Insmed
or view top insider-selling stocks.

Which major investors are buying Insmed stock?

INSM stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Artisan Partners Limited Partnership, Norges Bank, Lord Abbett & CO. LLC, Hood River Capital Management LLC, Frontier Capital Management Co. LLC, Silverarc Capital Management LLC, and GW&K Investment Management LLC.
View insider buying and selling activity for Insmed
or or view top insider-buying stocks.

How do I buy shares of Insmed?

Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insmed's stock price today?

One share of INSM stock can currently be purchased for approximately $38.13.

How much money does Insmed make?

Insmed has a market capitalization of $3.93 billion and generates $136.47 million in revenue each year. The biopharmaceutical company earns $-254,340,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis.

How many employees does Insmed have?

Insmed employs 373 workers across the globe.

What is Insmed's official website?

The official website for Insmed is www.insmed.com.

Where are Insmed's headquarters?

Insmed is headquartered at 700 US Highway 202/206, Bridgewater NJ, 08807.

How can I contact Insmed?

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]

This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.